The U.S. Food and Drug Administration has begun daily publication of adverse event reports tied to drugs and biological products, enhancing post-market safety surveillance. This shift from quarterly updates aims to improve transparency and expedite detection of safety signals, as announced by FDA Commissioner Marty Makary. The move supports better public access to critical drug safety information and underscores FDA's commitment to streamline monitoring processes amid ongoing debates around vaccine and drug safety.